Avenue Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Alix MacLean

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi	33.0%
CEO görev süresi	2.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Alix MacLean'un ücretlendirmesi Avenue Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$1m	US$400k	-US$10m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$516k	US$154k	-US$4m

Tazminat ve Piyasa: Alix 'nin toplam tazminatı ($USD 1.21M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 483.75K ).

Tazminat ve Kazançlar: Alix şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Alix MacLean (57 yo)

2.3yrs

Görev süresi

US$1,213,200

Tazminat

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as it...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexandra MacLean	CEO & Director	2.3yrs	US$1.21m	Veri yok
David Jin	Interim CFO	2.7yrs	US$260.00k	0% € 0
Lindsay Rosenwald	Executive Director	1.7yrs	US$104.00k	0.33% € 9.7k
Scott Reines	Interim Chief Medical Officer	8.8yrs	US$123.12k	Veri yok

2.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: 49Y 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexandra MacLean	CEO & Director	1.7yrs	US$1.21m	Veri yok
Lindsay Rosenwald	Executive Director	9.8yrs	US$104.00k	0.33% € 9.7k
Jay Kranzler	Chairman of the Board	7.8yrs	US$212.19k	0.043% € 1.3k
Neil Herskowitz	Non-Executive Independent Director	9.3yrs	US$164.00k	0.0084% € 248.1
Faith Charles	Independent Director	2.5yrs	US$154.00k	0% € 0
Curtis Oltmans	Independent Director	3.6yrs	US$154.00k	0.0031% € 90.9

5.7yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 49Y 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Avenue Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Recent updates

New major risk - Financial position

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Forecast breakeven pushed back to 2024

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: €5.65

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş